Jounce Therapeutics
1030 Massachusetts Avenue
Cambridge
Massachusetts
02138
United States
Tel: 857-259-3840
Fax: 617-812-5345
Website: http://www.jouncetx.com/
About Jounce Therapeutics
Jounce Therapeutics is focused on the discovery and development of novel cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
This transformational approach has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life.
Jounce is building upon the unparalleled expertise of its renowned scientific founders – world leaders in the fields of immunology, cancer biology and clinical and translational medicine in cancer – and its increasing understanding of how cancer cells communicate and interact with the immune system to position the company at the forefront of cancer immunotherapy drug discovery and development.
Based in Cambridge, Mass., Jounce is a private company launched in 2013 with $47 million in Series A venture capital financing by Third Rock Ventures.
126 articles about Jounce Therapeutics
-
Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference
2/28/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.
-
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022
2/23/2022
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022.
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in January 2022
1/4/2022
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that company management will participate at the following upcoming investor conferences in January.
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in November
11/9/2021
Jounce Therapeutics, Inc. today announced that company management will participate at the following upcoming investor conferences in November: 5th Annual Cowen IO Next Summit : Fireside chat on Monday, November 15, 2021 at 10:45 a.m. ET. 33rd Annual Piper Sandler Healthcare Conference
-
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
11/4/2021
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
10/28/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2021 financial results and provide a corporate update before market open on Thursday, November 4, 2021.
-
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
10/7/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the initiation of patient enrollment in INNATE tumor-specific expansion cohorts for both JTX-8064 monotherapy and combination therapy of JTX-8064 with its internal PD-1 inhibitor, pimivalimab.
-
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
9/15/2021
Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors.
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in September 2021
9/2/2021
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that company management will participate at several upcoming investor conferences in September:
-
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
8/5/2021
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
-
Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021
7/29/2021
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it will report second quarter 2021 financial results and provide a corporate update before market open on Thursday, August 5, 2021.
-
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
-
Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference
7/7/2021
Jounce Therapeutics, Inc. today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Officer will participate in a panel discussion at the William Blair’s Biotech Focus Conference taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.
-
Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day
6/23/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced a comprehensive update on its discovery and clinical-stage pipeline at its 2021 virtual R&D Day
-
Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
6/16/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it will host a virtual R&D Day at 10:00 a.m. – 12:00 p.m. ET on Wednesday, June 23, 2021.
-
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
6/15/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the U.S. Food and Drug Administration’s (FDA) clearance of its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences, Inc
-
Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference
6/14/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president will participate in a fireside chat at the Raymond James Human Health Innovation Conference,
-
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
6/4/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today presented two trial in progress posters, on the Phase 1 INNATE clinical trial and the Phase 2 SELECT clinical trial, at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting.
-
Jounce Therapeutics Reports First Quarter 2021 Financial Results
5/4/2021
Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab